Oxford Biomedica Confirms Preliminary Takeover Talks After Unsolicited EQT Approach

Oxford BioMedica ( (GB:OXB) ) just unveiled an update.

Oxford Biomedica has confirmed that it is in preliminary discussions with private equity group EQT, which has made an unsolicited approach regarding a possible all-cash offer for the entire issued and to-be-issued share capital of the company, following earlier proposals that the board rejected as undervaluing the business and its prospects. While no firm offer has yet been made and there is no certainty a transaction will proceed, EQT has been given a deadline of 11 February 2026 under UK takeover rules to either announce a firm intention to bid or walk away, putting Oxford Biomedica formally in play and creating a period of heightened deal speculation and strategic uncertainty for shareholders and other stakeholders.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £735.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Spark’s Take on GB:OXB Stock

According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.

Oxford BioMedica’s overall score is driven by strong corporate events and positive technical indicators, offset by financial instability and poor valuation metrics. The company’s strategic initiatives and market confidence provide a positive outlook, but financial challenges remain a significant risk.

To see Spark’s full report on GB:OXB stock, click here.

More about Oxford BioMedica

Oxford Biomedica is a global, innovation-led contract development and manufacturing organisation (CDMO) specialising in cell and gene therapy, with core expertise in viral vector development and production across lentivirus, adeno-associated virus, adenovirus and other vector types. A pioneer with three decades of experience in the field, the FTSE4Good-listed company serves leading pharmaceutical and biotechnology clients from facilities in Oxfordshire in the UK, Lyon and Strasbourg in France, and Bedford, Massachusetts and Durham, North Carolina in the US, providing services from early-stage development through to commercial manufacturing, supported by proprietary platform technologies and extensive regulatory and quality capabilities.

Average Trading Volume: 271,046

Technical Sentiment Signal: Buy

Current Market Cap: £904.4M

See more insights into OXB stock on TipRanks’ Stock Analysis page.